Meeting
2012 ASCO Annual Meeting
A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Authors
Cong Xue
Sun Yat-sen University Cancer Center, Guangzhou, China
Cong Xue , Qitao Yu , Jian-ji Pan , Yuanlu Sun , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00747799
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5538)
DOI
10.1200/jco.2012.30.15_suppl.5538
Abstract #
5538
Poster Bd #
21F
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase II study of pemetrexed combined with cisplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma.
First Author: A. W. M. Lee
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2017 ASCO Annual Meeting
Nimotuzumab combined with cisplatin plus fluorouracil chemotherapy in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: A multicentre, open-label, phase II clinical trial.
First Author: Chong Zhao
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara